Acumoxib Alternative Medicine is categorized under Acupuncturists in Bethesda, MD and active since 2007.
Acumoxib Alternative Medicine was established in 2007, and today employs 1 to 4, earning $50.000 to $99.999 per year. This is a Acupuncturists business, which does work in the B2C market, and is classified as a Acupuncturists, under code number 621399 by the NAICS.
If you are seeking more information, feel free to contact Kuei-Meng Wu at the company’s single location by writing to 9009 Quintana Drive, Bethesda, Maryland MD 20817 or by phoning (301) 564-9618. You can also visit this business on Facebook by going to their profile page at Facebook or on find them on Twitter.
| Business Name: | Acumoxib Alternative Medicine |
| Contact Person: | Kuei-Meng Wu |
| Address: | 9009 Quintana Drive, Bethesda, Maryland 20817 |
| Phone Number: | (301) 564-9618 |
| Website Address: | md-bethesda.doctors.at |
| Annual Revenue (USD): | $50.000 to $99.999 |
| Founded: | 2007 |
| Location Type: | Single Location |
| Employee Number: | 1 to 4 |
| Business Type: | B2C (Business to Consumer) |
| Business Category: | Acupuncturists |
| SIC Code: | 8049 |
| NAICS Code: | 621399 |
| Share This Business: |
Acumoxib Alternative Medicine was started in 2007 to provide professional Acupuncturists under the SIC code 8049 and NAICS code 621399. Since its inception, the company has gone on to take a total of 1 to 4 personnel under its employment and has achieved earnings of $50.000 to $99.999 per annum.
Feel free to contact Kuei-Meng Wu for inquiries that concern Acumoxib Alternative Medicine by calling the company number (301) 564-9618, as your correspondence is most welcome. Additionally, the physical location of the single location of Acumoxib Alternative Medicine can be found at the coordinates 39.003725,-77.158015 as well as the street address 9009 Quintana Drive in Bethesda, Maryland 20817.
For its online presence, you may visit Acumoxib Alternative Medicine’s website at md-bethesda.doctors.at and engage with its social media outlets through on Twitter and on Facebook.